Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

BACKGROUND: This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer. METHODS: Patients with confirmed progressive disease following the first-line t...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Ohkawa, S, Okusaka, T, Isayama, H, Fukutomi, A, Yamaguchi, K, Ikeda, M, Funakoshi, A, Nagase, M, Hamamoto, Y, Nakamori, S, Tsuchiya, Y, Baba, H, Ishii, H, Omuro, Y, Sho, M, Matsumoto, S, Yamada, N, Yanagimoto, H, Unno, M, Ichikawa, Y, Takahashi, S, Watanabe, G, Wakabayashi, G, Egawa, N, Tsuda, M, Hosotani, R, Hamada, C, Hyodo, I
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2015
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453667/
https://ncbi.nlm.nih.gov/pubmed/25880004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.103
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы